Niven Biopharma
Value creation through market focused development
Market potential as the driver
At Niven Biopharma, we believe that market potential should form the basis for developing new drugs and therapies. From this starting point, multiple interrelated functions must work seamlessly together so that the therapy can be brought to patients as quickly as possible.
With high risks of failure, there is significant pressure to make the best decisions at each stage of the development journey and to secure return on investment.
Drug and therapeutic companies often struggle to get this right, as they:
-
Rely too much on areas of expertise they are confident in, rather than what may be best for the drug or company overall
-
Adopt a short term focus, rather than on longer term value
-
Have poor coordination between functional silos and or conflicting priorities
Holistic development as the key to creating value
Niven Biopharma helps companies optimize company and asset value by focusing on these challenges. We do this by first adopting a market back view of what needs to be accomplished, and following through with holistic strategy, planning and delivery, covering clinical, regulatory and commercial aspects.
Our services
Using this approach we support customers in specific areas:
-
Integrated programme planning and asset leadership
-
Due diligence
-
Go / No-go decision making
-
Lifecycle management
About
Doug Niven | Asset Leadership
Doug Niven has over 20 years professional experience in research, development and commercial environments. He has extensive experience in working across therapeutic areas including rare diseases, inflammation and immunology, neurology and oncology. He has worked on assets with different treatment modalities including small molecules, biologics, medical devices and digital therapeutics. He is a trusted advisor to small biotech companies as well as big pharma.
Biopharma over coffee blog
Please do check out our blog Biopharma Over Coffee in which we cover new and innovative developments in biotech, pharma and the markets. This blog is specifically written for people working in these fields. Below are links to several recent articles.